Patients with CKD could have an elevated dementia risk. 4 key findings →
Design: cohort study Participants: 37,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
71/100
We identified a non-linear association of type 2 diabetes duration and the risk of dementia. 1 key finding →
Design: cohort study Participants: 13,761 Evidence: moderate
Full summary, score breakdown and related studies → Original source
69/100
The prevalence and incidence of early-onset dementia among adults with autism spectrum disorder (ASD) is currently unknown. 5 key findings →
Design: case-control study Participants: 12,648 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Compared with PWOH, PWH were at 58% higher risk for dementia despite HIV treatment with ART. 2 key findings →
Design: cohort study Participants: 5,381 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Adults with TSCI are at a heightened risk for ADRD. 2 key findings →
Design: cohort study Participants: 7,019 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dialysis modality is associated with incident dementia in a cohort of older ESRD patients. 4 key findings →
Design: cohort study Participants: 121,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
Dementia is among various diseases affecting the elderly, who is also at a high risk for fractures. 3 key findings →
Design: cohort study Participants: 66,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neurodegenerative disease in patients with chronic obstructive pulmonary disease (COPD) was observed. 2 key findings →
Design: cohort study Participants: 8,640 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Preventable hospital readmissions have been recognized as indicators of hospital quality, a source of increased healthcare expenditures, and a burden for patients, families, and caregivers. 2 key findings →
Design: cohort study Participants: 5,133 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Careful consideration of model specification and the profound effects of mortality selection in the older adult population is essential when investigating the relationship between aging-related diseases such as cancer and AD. 4 key findings →
Design: cohort study Participants: 92,425 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Program participants (n = 382 men, n = 701 women; mean [SD] age, 82.10 [7.90] years; age range 54-101 years) were less likely to be admitted to a long-term care facility (hazard ratio, 0.60; 95% CI, 0.59-0.61) than those not participating in the dementia care program (n = 759 men, n = 1407 women; mean [SD] age, 82.42 [8.50] years; age range, 34-103 years). 1 key finding →
Design: case-control study Participants: 382 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The eRADAR tool uses existing EHR data to detect patients with good accuracy who may have unrecognized dementia. 1 key finding →
Design: cohort study Participants: 4,330 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals aged 68+ years diagnosed with OAG have a decreased rate of AD or other dementia diagnosis compared to control patients without an OAG diagnosis. 3 key findings →
Design: cohort study Participants: 63,235 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Underclassification of dementia from claims records can be partially remedied by increasing the period during which claims are compiled, but additional diagnostic sources will likely be needed to increase prevalence counts closer to 100% of true cases. 2 key findings →
Design: prospective cohort Participants: 4,166 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study demonstrates that influenza vaccination is associated with reduced AD risk in a nationwide sample of US adults aged 65 and older. 2 key findings →
Participants: 2,356,479 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The associations with vascular dementia may be one component of a broader association between autoimmune diseases and vascular damage. 5 key findings →
Design: cohort study Participants: 827 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Receiving two types of vaccinations versus one type was associated with lower dementia risk. 5 key findings →
Participants: 80,070 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A cognitive symptom measure identified in discharge notes facilitated stratification of risk for dementia up to 8 years before diagnosis. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The results should form the basis for future health policy decisions on the treatment of patients with multiple chronic diseases and also show the need to introduce new ways of providing long-term care to this population. 3 key findings →
Participants: 115,203 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hospitalised people with cognitive impairment experience significantly greater length of stay and when discharged to their usual residence are more likely to be readmitted to hospital within 28 days compared with those without cognitive impairment. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Few studies have examined the disease burden of AD in commercial managed care settings. 3 key findings →
Participants: 4,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia diagnoses were a significant predictor of 30-day ED revisits. 5 key findings →
Participants: 249 Evidence: low
Full summary, score breakdown and related studies → Original source
The average total cost to Medicare of persons with a claims-based diagnosis of AD was $6021 versus $2310 (P < .001) for persons without a diagnosis. 2 key findings →
Design: cross-sectional Participants: 10,858 Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →